Status:
COMPLETED
A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea
Lead Sponsor:
Coria Laboratories, Ltd.
Conditions:
Rosacea
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
Brief Summary
To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.
Eligibility Criteria
Inclusion
- Female
- Age 18-65
- Diagnosed with classical, centrofacial, erythemato-telangiectatic rosacea
Exclusion
- Male, females less than 18 years
- Females over 65 years
- No diagnosed rosacea
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00621218
Start Date
February 1 2008
End Date
December 1 2008
Last Update
December 18 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Product Investigations, Inc.
Conshohocken, Pennsylvania, United States, 19428